Endocrine Oncology is the best choice you can make to specialize in a field that affects millions of people”

Diabetes and Obesity pose a real risk for developing Cancer Pathologies, so medical practitioners must be prepared to deal with complex Oncological Cases, where nutrition plays a key role in the future prevention of different Types of Cancers. That is where the endocrine specialty comes into play, where healthcare professionals can identify all the specific Oncological Pathologies of this System to obtain better diagnoses and preventive treatments for patients.

For this reason, TECH has gathered in this Professional master’s degree in Endocrine Oncologic Pathology the best knowledge of Hypothalamic-Pituitary Tumor Pathology, Thyroid Node management, Adrenal Cortex Tumors and other types of Oncological Conditions directly related to the Endocrine System. 

Thanks to this specialty, physicians graduating from this degree will have a much better understanding of a field of Oncology that has become vitally important in recent years. This will allow them to become key members of their medical team, being the main link between the Departments of Oncology and Endocrinology to deal with patients with complex pathologies that require the most specialized attention.

Furthermore, students have the advantage of being able to take this Professional master’s degree completely online, being able to download the entire syllabus from the first day of the program. At TECH, it is students who set the guidelines and pace of study, without adhering to predetermined schedules or classes. 

Achieve your career goals by helping patients with complex and delicate oncological pathologies that require the best professionals”   

This Professional master’s degree in Endocrine Oncologic Pathology contains the most complete and up-to-date scientific program on the market. The most important features include:

• Case studies presented by experts in Endocrine Oncologic Pathology
• The graphic, schematic, and eminently practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where the self-assessment process can be carried out to improve learning
• Its special emphasis on innovative methodologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Access to content from any fixed or portable device with an Internet connection

Are you ready to take your medical career to the next level? Join the TECH team and take a firm step forward in your department”

The program’s teaching staff includes professionals from the sector who contribute their work experience to this training program, as well as renowned specialists from leading societies and prestigious universities.

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive training programmed to train in real situations.

This program is designed around Problem-Based Learning, whereby the professional must try to solve the different professional practice situations that arise during the academic year. For this purpose, the student will be assisted by an innovative interactive video system created by renowned and experienced experts.   

This degree will be key when dealing with complex cases, in which your expertise and professionalism will stand out"

Connect the Oncology and Endocrinology Departments at your hospital and become essential for your team"

Endocrine Oncology is a complex subject to deal with, where physicians must also assume the role of patient counselors and intermediaries with the family That is why the content of this Professional master’s degree goes beyond to include total monitoring of all possible types of Tumor Pathologies, so students have a global understanding of the entire process that affects the patient. Furthermore, the teaching load is reduced and contextualized thanks to the support of quality audiovisual material provided by the professors themselves.

Forget the obsolete programs that demand too much from you and obtain your Professional master’s degree in Endocrine Oncologic Pathology directly, without a final work paper or project”  

Module 1. Hypothalamic-Pituitary Tumor Pathology

1.1. Pituitary Tumors Pathogenesis
1.2. Clinical and Prognostic Classification for Selar Tumors: List Clinical, Radiological, Functional and Anatomical Pathological Elements to Characterize the Prognosis of Selar Lesions

1.2.1. Adenomas

1.2.1.1. Clinical, Functional and Radiological Classification
1.2.1.2. Pathological Anatomy of Pituitary Adenomas

1.2.2. Non-Adenomatous Selar Tumors: Rathke's Pouch (Cysts, Craniopharyngiomas), Meningiomas
1.2.3. Non-Proliferative Lesions: Inflammatory, Hemorrhagic

1.3. Imaging Study for Hypothalamic-Pituitary Tumor Pathology
1.4. Ophthalmologic Evaluation for Hypothalamic-Pituitary Tumor Pathology
1.5. Prolactinoma: Differential Diagnosis for Hyperprolactinemia
1.6. Acromegaly
1.7. ACTH-Dependent Cushing's Syndrome: Cushing's Disease
1.8. Non-Functioning Pituitary Adenomas and Gonadotropinomas
1.9. Less Common Pituitary Adenomas

1.9.1. Thyrotropinomas: Adenomas Plurihormonales
1.9.2. Aggressive Pituitary Adenomas

1.10. Other Selar Area Tumors

1.10.1. Rathke's Pouch Cyst and Craniopharyngioma
1.10.2. Meningioma: Pituicytoma

1.11. Surgical Treatment for Selar and Parasellar Lesions

1.11.1. Surgical Treatment
1.11.2. Postoperative Hypothalamic-Pituitary Functional Evaluation

1.12. Radiotherapy and Radionuclide Therapy for Selar and Parasellar Lesions

1.12.1. Radiotherapy
1.12.2. Radionuclide Therapy
1.12.3. Long-term Monitoring after Radiotherapy

1.13. Importance of Tumor Committees and Patient Associations

1.13.1. Multidisciplinary Approach
1.13.2. Role of Patient: Association of Patients Affected by Acromegaly

Module 2. Thyroid Nodule Management: Parathyroid Tumors

2.1. Causes of Nodular Thyroid Disease: Thyroid Incidentaloma
2.2. Nodular Thyroid Disease Evaluation: Data Suggesting Malignancy Suspicion

2.2.1. Clinical Data, Personal History, Family History
2.2.2. Exploration Data: Laboratory Data

2.3. Ultrasound in the Evaluation of Nodular Thyroid Disease

2.3.1. Cervical Ultrasound
2.3.2. TI-RADS Classification: American Thyroid Association (ATA) Classification

2.4. Thyroid Gammagraphy: Other Imaging Techniques
2.5. Nodular Thyroid Disease Cytological Studies

2.5.1. Fine Needle Aspiration Puncture (FNA) with Ultrasound Monitoring
2.5.2. Bethesda’s Classification

2.6. Hyperthyroidism Caused by Hyperfunctioning Thyroid Nodule: Hyperfunctioning Multinodular Goiter Treatment
2.7. Molecular Markers Use: What to Do with a Bethesda III?

2.8. Nodular Thyroid Disease Surgical Treatment

2.8.1. Indications
2.8.2. Types of Treatment

2.9. Other Treatments

2.9.1. Ethanolization
2.9.2. Laser Thermal Ablation
2.9.3. Radiofrequency Thermal Ablation

2.10. Approach to Primary Hyperparathyroidism

2.10.1. Classification
2.10.2. Biochemical Diagnosis
2.10.3. Imaging Tests
2.10.4. Treatment

Module 3. Differentiated Thyroid Carcinoma (DTC)

3.1. Molecular Aspects of Differentiated Thyroid Carcinoma: Clinical Implications
3.2. Pathological Anatomy of Thyroid Carcinoma: Classification
3.3. Follicular Neoplasm with Papillary-Like Changes (FANFIC)
3.4. Papillary Microcarcinoma

3.4.1. Is Only Monitoring Possible?
3.4.2. When to Treat
3.4.3. How to Treat

3.5. Initial Staging: 8th Classification Differences with the 7th Classification
3.6. Surgical Treatment

3.6.1. Initial Surgical Treatment
3.6.2. Relapse Treatment

3.7. Radioiodine Treatment

3.7.1. When to Treat
3.7.2. Treatment Dose
3.7.3. Radioiodine Refractoriness

3.8. Monitoring: Dynamic Risk Staging
3.9. Treatment of Advanced Unresectable DTC
3.10. Importance of Tumor Committees and Patient Associations

3.10.1. Multidisciplinary Approach

Module 4. Medullary Thyroid Carcinoma (MTC): Other Thyroid Carcinomas

4.1. Medullary Thyroid Carcinoma (MTC)

4.1.1. Introduction: Epidemiology    
4.1.2. Classification: Anatomopathological Features
4.1.3. Clinical Manifestations
4.1.4. Genetic Studies

4.2. MTC: Initial Staging Dynamic Risk Staging
4.3. Diagnosis of CMT

4.3.1. Laboratory Tests
4.3.2. Imaging Tests
4.3.3. FNA with Ultrasound Monitoring

4.4. MTC: Surgical Treatment

4.4.1. Surgical Scope
4.4.2. Surgical Treatment for Relapse
4.4.3. Surgical Treatment for Metastasis

4.5. MTC: Radiotherapy: Radionuclide Therapy
4.6. MTC: Advanced Unresectable Disease Treatment

4.6.1. Tyrosine Kinase Inhibitors
4.6.2. Other Treatments

4.7. MTC: Monitoring and Prognosis
4.8. Poorly Differentiated Thyroid Carcinoma: Anaplastic Carcinoma
4.9. Thyroid Lymphoma and Other Rare Thyroid Malignancies: Metastases of Other Tumors

Module 5. Adrenal Cortex Tumors

5.1. Adrenal Incidentaloma: Diagnostic Approach
5.2. ACTH Independent Cushing's Syndrome Caused by Adrenal Adenoma
5.3. Primary Hyperaldosteronism: Cohn's Disease
5.4. Adrenocortical Carcinoma (ACC)

5.4.1. Introduction
5.4.2. Medical History and Exploration

5.5. ACC: Genetic Aspects Laboratory Data Hormone Secretion
5.6. ACC: Imaging Tests Ultrasound CT, MRI, PET-CT
5.7. ACC: Pathological Anatomy Staging Prognostic Factors
5.8. Surgical Treatment

5.8.1. Surgical Treatment for Primary Tumors
5.8.2. Surgery and Other Local Treatments for Advanced Disease

5.9. Adjuvant: Radiotherapy Relapse Treatment
5.10. Treating Advanced Stages of the Disease

Module 6. Pheochromocytomas and Paragangliomas

6.1. Introduction

6.1.1. Anatomy Recap
6.1.2. Epidemiology

6.2. Molecular Basis: Genotype-Phenotype Correlation
6.3. Clinical Manifestations: Ways It Presents Itself
6.4. Laboratory Data
6.5. Imaging Tests
6.6. Surgical Treatment

6.6.1. Adrenergic Block
6.6.2. Surgery for Pheochromocytomas and Paragangliomas: Embolization

6.7. Radionuclide Therapy: Radiotherapy
6.8. Treating Advanced Stages of the Disease
6.9. Prognosis and Monitoring

6.9.1. Different Mutation Carrier Monitoring
6.9.2. Long-Term Monitoring
6.9.3. Prognosis

6.10. Importance of Tumor Committees and Patient Associations

6.10.1. Multidisciplinary Approach
6.10.2. Role of Patient Associations

Module 7. Multiple Endocrine Neoplasia Syndromes

7.1. Multiple Endocrine Neoplasia Type I (MEN I): Genetics

7.1.1. MEN I Genetics
7.1.2. When to Perform a Genetic Study to Rule Out Mutation in the Menin Gene
7.1.3. Genetic Counseling for MEN I: Preimplantational Diagnosis

7.2. Clinical Manifestations of the Syndrome: Ways MEN I Presents Itself
7.3. Laboratory Tests at Initial Evaluation and Subsequent Monitoring
7.4. MEN I. Imaging Tests at Initial Evaluation and Subsequent Monitoring
7.5. MEN I. Primary Hyperparathyroidism (PHPT) Treatment: Relapse Management
7.6. MEN I. Pancreatic Neuroendocrine Tumors: Surgical Indications
7.7. Managing of Other Tumors

7.7.1. Neuroendocrine Tumors (NETs) in Atypical Locations: Bronchial and Thymic NETs
7.7.2. Screening, Monitoring and Treatment for Other Neoplasms

7.8. Multiple Endocrine Neoplasm Type II (MEN II): MEN II Genetics

7.8.1. RET Oncogene
7.8.2. Genotype-Phenotype Correlation
7.8.3. Less Common Mutations

7.9. MEN II: Medullary Carcinoma

7.9.1. Evaluation and Monitoring after Knowing the Carrier's Condition
7.9.2. Prophylactic Thyroidectomy

7.10. MEN II: Primary Pheochromocytoma and Hyperparathyroidism

7.10.1. Evaluation and Monitoring after Knowing the Carrier's Condition
7.10.2. Indications for Hyperparathyroidism Treatment in MEN II Patients

7.11. MEN II: Other MEN II Manifestations
7.12. Others Multiple Endocrine Neoplasm Syndromes

Module 8. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

8.1. Gastroenteropancreatic Neuroendocrine Tumors

8.1.1. Concept
8.1.2. Epidemiology

8.2. Molecular and Cellular Basis
8.3. Pathological Anatomy

8.3.1. Classification Systems

8.4. Lung and Thymus NETs
8.5. Gastric NETs
8.6. Intestinal NETs: Appendix NET
8.7. Non-Functioning Pancreatic NETs
8.8. Gastrinoma
8.9. Insulinoma
8.10. Gucagonoma, Somatostatinoma, Vipoma: Other Functioning Tumors

Module 9. GEP-NET: Anatomical and Functional Diagnosis Treating Locoregional Disease

9.1. Carcinoid Syndrome: Carcinoid Cardiopathy
9.2. ACTH and Other Hormone Ectopic Secretion Syndromes
9.3. GEP-NET Diagnosis and Monitoring: Biological Markers

9.3.1. Usefulness in Diagnosis and Monitoring

9.4. GEP-NET Diagnosis and Monitoring: Endoscopy and Echoendoscopy-Guided Fine Needle Aspiration Puncture (FNA) in the Diagnosis and Monitoring of GEP-NET
9.5. GEP-NET Diagnosis and Monitoring: Imaging Tests I

9.5.1. Ultrasound, Computerized Tomography, Magnetic Resonance Imaging
9.5.2. Treatment Response Criteria (RECIST, Choi, and Others)

9.6. GEP-NET Diagnosis and Monitoring: Imaging Tests II Nuclear Medicine in the Diagnosis and Monitoring of GEP-NETs
9.7. Surgical Treatment for Pulmonary NET
9.8. Surgical Treatment for Gastric NET
9.9. Surgical Treatment for Intestinal NET
9.10. Surgical Treatment for Pancreatic NET

9.10.1. Treatment for Incidentally Discovered Non-Functioning Pancreatic NETs: Surgery / Monitoring

9.11. Surgical Treatment for G3 Tumors: Surgical Treatment for MINEN

Module 10. Gastroenteropancreatic Neuroendocrine Tumors: Treating Advanced Stages of the Disease

10.1. Surgical Treatment in Advanced Stages of the Disease

10.1.1. Surgical Treatment Indication for Primary Tumors
10.1.2. Surgical Treatment for Liver and Other Metastases

10.2. Locoregional Treatments

10.2.1. Embolization
10.2.2. Radiofrequency
10.2.3. Other Locoregional Treatments

10.3. Biological Treatments: Somatostatin Analogues and Others
10.4. Chemotherapy and Targeted Therapies: Role of Immunotherapy
10.5. Theragnosis: Radionuclide Therapy
10.6. Treatment Sequencing
10.7. Nutritional Management for GEP-NET Patients
10.8. Importance of Tumor Committees and Patient Associations

10.8.1. Multidisciplinary Approach

This is the future of education, where you are the one who decides when, where and how to study all the didactic content”